title: Immunotherapy using purified protein derivative in the treatment of warts: An open uncontrolled trial.
abstract: BACKGROUND
  Warts are known to clear spontaneously with the development of cell-mediated immunity (CMI) to the virus. Purified protein derivative (PPD) of tuberculin bacilli has been used as a non-specific stimulant of CMI to achieve this outcome.
  
  
  OBJECTIVE
  To study the effect of PPD in the treatment of warts.
  
  
  METHODS
  Patients with difficult-to-treat warts were selected for immunotherapy. Each patient received 2.5 TU of PPD intralesionally in a few warts. A total of four sessions were given at 2 weekly intervals and patients were followed up for 6 months after the last dose.
  
  
  RESULTS
  Sixty-one patients were recruited of which 55 completed 6 months follow up and were available for analysis. Of these, 25 had verruca vulgaris, 18 had verruca plana and 12 had plantar warts. Forty two (76%) patients showed complete clearance after four sessions while the remaining 13 (24%) patients were non-responders. One patient developed a recurrence after total clearance during the follow-up period. Adverse effects were erythema, edema and pain at the site of injections.
  
  
  CONCLUSIONS
  As this was an uncontrolled trial, there is no comparison with a non-intervention group. Also, a Mantoux test was not done due to practical difficulties.
  
  
  CONCLUSIONS
  Immunotherapy with PPD is helpful in the treatment of cutaneous warts.
authors.affiliation: Department of Dermatology, JNMC, Wardha, Maharashtra, India.
authors.forename: Vikrant
authors.initials: V
authors.lastname: Saoji
authors.forename: Nitin R
authors.initials: NR
authors.lastname: Lade
authors.forename: Rutuja
authors.initials: R
authors.lastname: Gadegone
authors.forename: Arun
authors.initials: A
authors.lastname: Bhat
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D014373:Tuberculin / Q000008:administration & dosage*; D014860:Warts / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D055815:Young Adult
chemical_list: D014373:Tuberculin